Improving treatment outcomes for MDR-TB - Novel host-directed therapies and personalised medicine of the future
Rao, Mangala (Champalimaud Centre for the Unknown (Lisboa, Portugal))
Ippolito, Giuseppe (National Institute for Infectious Diseases. Lazzaro Spallanzani)
Mfinanga, S. (National Institute of Medical Research Muhimbili)
Ntoumi, F. (Institute for Tropical Medicine. University of Tübingen)
Yeboah-Manu, Dorothy (Noguchi Memorial Institute for Medical Research. Department of Bacteriology)
Vilaplana, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Zumla, Alimuddin (Division of Infection and Immunity. University College London and NIHR Biomedical Research Centre. UCL Hospitals NHS Foundation Trust)
Maeurer, M. (Krankenhaus Nordwest (Frankfurt am Main, Alemanya))
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured. Most MDR-TB patients who recover continue to suffer from functional disability due to long-term lung damage. Whilst new MDR-TB treatment regimens are becoming available, conventional drug therapies need to be complemented with host-directed therapies (HDTs) to reduce tissue damage and improve functional treatment outcomes. This viewpoint highlights recent data on biomarkers, immune cells, circulating effector molecules and genetics which could be utilised for developing personalised HDTs. Novel technologies currently used for cancer therapy which could facilitate in-depth understanding of host genetics and the microbiome in patients with MDR-TB are discussed. Against this background, personalised cell-based HDTs for adjunct MDR-TB treatment to improve clinical outcomes are proposed as a possibility for complementing standard therapy and other HDT agents. Insights into the molecular biology of the mechanisms of action of cellular HDTs may also aid to devise non-cell-based therapies targeting defined inflammatory pathway(s) in Mtb-driven immunopathology.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biomarkers ; Clinical studies ; Host-directed therapies ; Immunotherapy ; Multidrug-resistant tuberculosis ; Personalised medicine
Publicat a:	International journal of infectious diseases, Vol. 80 (march 2019) , p. S62-S67, ISSN 1878-3511

DOI: 10.1016/j.ijid.2019.01.039
PMID: 30685590

6 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats